# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-005818
Filing Date
2025-01-15
Accepted
2025-01-15 15:53:14
Documents
62
Period of Report
2024-11-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | neog-20241130.htm iXBRL | 10-Q | 2291773
2 | EX-31.1 | neog-ex31_1.htm | EX-31.1 | 14734
3 | EX-31.2 | neog-ex31_2.htm | EX-31.2 | 14530
4 | EX-32 | neog-ex32.htm | EX-32 | 11548
5 | GRAPHIC | img193760187_0.jpg | GRAPHIC | 646845
| Complete submission text file | 0000950170-25-005818.txt |  | 10235952

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | neog-20241130.xsd | EX-101.SCH | 1138007
64 | EXTRACTED XBRL INSTANCE DOCUMENT | neog-20241130_htm.xml | XML | 1729510

Mailing Address 620 LESHER PLACE LANSING MI 48912
Business Address 620 LESHER PLACE LANSING MI 48912 5173729200
NEOGEN CORP (Filer) CIK: 0000711377 (see all company filings)

EIN.: 382367843 | State of Incorp.: MI | Fiscal Year End: 0531
Type: 10-Q | Act: 34 | File No.: 000-17988 | Film No.: 25532856
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)